治疗管道栓塞装置用于内动脉瘤后的他与没有他:一个元分析
Nathalia Soares Barbosa1, Felipe Araujo Gouhie2, Bezalel Hakkeem3
1Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória ES, Brazil.
Arquivos de neuro-psiquiatria
|June 21, 2025
概括
类固醇药物治疗可以减少输管栓塞装置 (PED) 治疗脑动脉瘤后的出血并发症. 然而,在动脉瘤闭塞率或缺血并发症方面没有发现显著差异.
科学领域:
- 神经学 神经学
- 心血管研究研究心血管研究
- 医疗干预 医疗干预
背景情况:
- 众所周知,他类药物治疗可以改善用线圈栓塞或外科切割治疗的大脑动脉瘤的结果.
- 在接受管道栓塞装置 (PED) 治疗内动脉瘤的患者中,他类药物的疗效尚不清楚.
研究的目的:
- 评估他类药物治疗对出血和缺血并发症的影响.
- 评估他类药物对使用PED治疗的动脉瘤完全封闭率的影响.
主要方法:
- 在PubMed,Embase和Cochrane图书馆数据库中进行了系统的文献搜索,直到2024年11月.
- 包括观察性研究,比较PED治疗后的他类药物与没有他类药物治疗.
- 分析了四项涉及2822名患者和3063例动脉瘤的研究的数据.
主要成果:
- 类固醇使用与总出血并发症的显著减少有关 (RR=0.50;95% CI:0.29-0.85).
- 在完全动脉瘤闭塞率 (RR=0.94;95% CI:0.88-1.00) 或总缺血并发症 (RR=1.48;95% CI:1.06-2.07) 中没有发现显著差异.
- 倾向分数匹配的分析没有证实出血并发症的减少 (RR=0.50;95% CI:0.24-1.07).
结论:
- 静止剂的使用可能会减少管道栓塞装置治疗内动脉瘤后的出血并发症.
- 由于研究的局限性,关于减少出血并发症的发现应谨慎解释.
- 在他类药物和非他类药物组之间没有观察到完全封闭率或缺血并发症的显著差异.
更多相关视频
相关概念视频
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
890
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
890
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Peripheral Artery Disease III: Interprofessional Care
34
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
34
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
48
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
48


